Placebo matching BI 1291583

DRUG3 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim

Conditions

Bronchiectasis

Phase 2

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Active, not recruitingNCT05846230

Boehringer IngelheimBronchiectasis

Start: 2023-09-08End: 2027-03-31Updated: 2026-08-21

Phase 3

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

RecruitingNCT06872892

Boehringer IngelheimBronchiectasis

Start: 2025-06-09End: 2027-12-20Target: 1755Updated: 2026-09-18

A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY TM Study)

RecruitingCTIS2024-518589-29-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Bronchiectasis

Start: 2025-08-21Target: 519Updated: 2026-01-27

Related Papers

Phase III AIRTIVITY™ study design – verducatib (BI 1291583) in people with bronchiectasis

ERJ Open Research2026-04-23

Novel cathepsin C inhibitor, <scp>BI</scp> 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers

Clinical and Translational Science2024-08-019 citations